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Oncogenicity tests have revealed that a nonmutated erbB oncogene induces renal adenocarcinoma in addition
to erythroblastosis. The erbB oncogene is a truncated form of the chicken epidermal growth factor receptor that
lacks the extracellular ligand-binding domain. Previously, the nonmutated erbB oncogene has been reported to
cause only erythroblastosis. The expansion of the disease potential of erbB to additional neoplasms has been
associated with mutations (truncations, deletions, and point mutations) within the erbB gene. Our results
indicate that a nonmutated virally expressed erbB oncogene (REB-c) causes a 100% incidence of renal
neoplasia.
The erbB oncogene encodes the transmembrane, protein
tyrosine kinase, and C-terminal autophosphorylation do-
mains of the epidermal growth factor (EGF) receptor (for a
review, see reference 15). Nonmutated forms of the erbB
oncogene cause erythroblastosis in chickens (1, 11, 20, 21,
25, 33). Point mutations in the kinase domain can broaden
this disease potential to the induction of fibrosarcoma (29,
30). Truncations, in-frame deletions, and point mutations in
the C-terminal domain extend the erbB disease potential to
the induction of angiosarcoma and fibrosarcoma (11, 15, 23,
25, 29, 30, 32). The oncogenic potential of erbB can also be
increased by the presence of another oncogene. This is best
exemplified by avian erythroblastosis virus ES4 (AEV-ES4)
and AEV-R, viruses that contain both the erbB and the erbA
oncogenes (6, 10, 14, 27). AEV-ES4 has been reported to
cause renal adenocarcinoma as well as erythroblastosis and
fibrosarcoma (3; for a review, see reference 15). td359, a
variant of AEV-ES4 that is defective for erbA and contains
a C-terminal truncation of erbB, causes renal adenocarci-
noma and fibrosarcoma in the absence of erythroblastosis (6,
18). Here we show that a nonmutated erbB can cause renal
adenocarcinoma as well as erythroblastosis.
The disease potential of erbB oncogenes has been evalu-
ated by using avian leukosis virus vectors. Many of these
have represented naturally occurring transductions of erbB
(1, 6, 10, 16, 23, 28, 34). More recently, erbB sequences have
been expressed by using replication-competent avian leuko-
sis virus vectors (e.g., RCAN) (13, 20, 21, 29, 30). In
particular, a construct designated REB-c has been used to
test for the oncogenic potential of mutations in erbB (20, 21,
29, 30). The parent REB-c vector expresses a nonmutated,
C-terminal complete erbB (21). Our studies were conducted
with a modified REB-c which contains gag and pol se-
quences from the Bryan high-titer strain of Rous sarcoma
virus (RCANBGP) (13, 29). REB-c causes a high incidence
of erythroblastosis and a moderately low incidence of wing
web tumors (20, 21, 29, 30, 32).
Tests of the oncogenic potential of REB-c revealed a 100%
incidence of renal adenocarcinoma in addition to a 100%
incidence of erythroblastosis and a 33% incidence of wing
* Corresponding author.
web tumors (Fig. 1). Both 1-day-old specific-pathogen-free
SPAFAS (SPAFAS, Norwich, Conn.) and K28 (24) chicks
were used for inoculations. Oncogenicity tests were initiated
by inoculation of (i) pREB-c-transfected chicken embryo
fibroblasts in virus-containing culture medium, (ii) culture
medium from transfected chicken embryo fibroblasts, or (iii)
REB-c plasmid DNA. Chickens were inoculated intrave-
nously, intraperitoneally, and in the wing web. Inoculations
of cells plus virus consisted of -106 cells and 0.1 to 0.2 ml of
culture medium per site. Virus inoculations consisted of 0.1
to 0.2 ml of culture medium per site. For DNA inoculations,
100 ,ug of cesium chloride-purified plasmid DNA in 0.05 to
0.2 ml of saline was used at each inoculation site. Use of
direct DNA inoculations eliminates the occurrence of muta-
tions in erbB during the recovery of virus in cell cultures.
Beginning at 1 to 2 weeks postinoculation, chicks were
monitored twice weekly for the presence of erythroblasts in
blood smears and signs of wing web tumors. Chickens were
terminated at approximately 3 to 6 weeks postinoculation, a
time when all of the chicks (inoculated with either cells plus
virus, virus, or DNA) had developed erythroblastosis. Nec-
ropsy was performed, and tissues were fixed in phosphate-
buffered formalin and processed for histologic analyses.
Renal tumors were first noticed at the time of autopsy.
Kidney tumors were observed whether infected cells plus
virus, virus, or DNA was used as the inoculum. Control
chicks inoculated with vector DNA (pRCANBGP) alone
became viremic but did not develop disease.
Histologic evaluation of the REB-c-induced renal tumors
revealed a spectrum of changes from hyperplasia of the
tubular epithelium to invasive adenocarcinoma (Fig. 2).
Proliferative epithelial lesions were most prominent in the
subcapsular region of the kidney and created a lacelike
appearance in low-power-microscopic sections (Fig. 2A).
The epithelial lesions were classified as hyperplasia if there
was hypercellularity within single tubules; adenoma if in
addition to hypercellularity there were architectural abnor-
malities such as papillary infoldings, cystic change, or an
increase in the number of tubules to form a nodule (Fig. 2B);
and adenocarcinoma if marked cytoplasmic abnormalities or
stromal invasion was noted (Fig. 2C). All kidneys exhibited
hyperplasia and adenoma. Features of malignancy (adeno-
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FIG. 1. Induction of renal neoplasia by REB-c. (A) Schematic representation of REB-c.`, splice acceptor; r-, splice donor; !"', cryptic
splice donor; AUG, start codon; TM, transmembrane domain; Kinase, protein tyrosine kinase domain; SS, serine 477/478 phosphorylation
site; Y, tyrosine autophosphorylation site; LTR, long terminal repeat. (B) The incidence of renal adenoma or adenocarcinoma,
erythroblastosis, and wing web tumors is presented as the ratio of number diseased to number inoculated.
carcinoma), including stromal invasion, and cytologic
changes of increased nuclear-cytoplasmic ratio and nuclear
pleomorphism were present in -50% of the kidneys. The
proliferating epithelial cells appeared to be in the distal
convoluted tubule or collecting ducts, as the proximal tu-
bules and glomeruli were normal. The histologic character-
istics of the tumors were comparable to those reported for
the AEV-ES4- and td359-induced renal cell tumors (3, 18).
Mutations at the serine 477/478 phosphorylation site of
erbB that enhance the ability to induce wing web tumors (32)
did not significantly affect the histologic characteristics of
the renal adenocarcinoma (Fig. 1). Mutational removal of
Ser-1046/1047, the human EGF receptor homolog of serine
477/478, has demonstrated that phosphorylation at this site
acts to suppress EGF-induced signal transduction (5, 31).
Ala-477/478 and Glu-477/478 mutations in erbB have been
described previously (32). Transfected cells plus virus, vi-
rus, and plasmid DNA for both of these mutant erbB genes
caused adenocarcinoma with histologic characteristics sim-
ilar to those induced by the nonmutated C-terminal complete
erbB (REB-c).
Internal deletions and truncations in C-terminal erbB
sequences have previously been associated with the broad-
ening of the oncogenic potential of erbB (11, 15, 23, 25, 30).
Therefore, the erbB genes from two adenocarcinomas were
analyzed to examine whether the 3' erbB sequences were the
same size as the parent REB-c vector. The 3' region
bounded by BamHI and HindIII (Fig. 3A) has been a
common target for deletions and truncations (6, 11, 15, 23,
25, 30, 36, 37). To test for the presence of deletions and
truncations, DNA was extracted from diseased kidneys and
from uninfected control kidneys. With the kidney DNA as a
template, oligonucleotides 5' to the BamHI site and within
the long terminal repeat of REB-c were used for amplifica-
tion of a 1.27-kb REB-c fragment (Fig. 3A). The polymerase
chain reaction (PCR)-amplified DNA was digested with
HindIII to demonstrate that the 1.27-kb product contained
the expected 882-bp erbB fragment. Both cut and uncut PCR
products were run on 2% agarose gels (3 parts NuSieve
agarose and 1 part SeaKem agarose; FMC, Rockland,
Maine), transferred to nitrocellulose, and probed with an
erbB-specific probe generated by random priming. Ethidium
-v Kinase lyyyy
I
J.
NOTES 1133
r -
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
1134 NOTES
FIG. 2. Microscopic sections of kidneys showing the pathologic patterns in REB-c-induced renal adenoma or adenocarcinoma. (A)
Lacelike appearance of REB-c-induced neoplasia (hematoxylin and eosin stain [HE]; magnification, x20). (B) Adenomatous lesions
characterized by architectural distortion with formation of two nodules and papillary infoldings of the epithelium (shown by arrows) (HE;
magnification, x 100). (C) Adenocarcinoma characterized by a nodule exhibiting a focus of stromal invasion (shown by arrows). Invading cells
have an increased nuclear-cytoplasmic ratio (HE; magnification, x400). (D) Normal, uninfected control kidney. C, collecting ducts; G,
glomeruli; P, proximal tubules (HE; magnification, x400).
bromide-stained gels (data not shown) and autoradiographs
(Fig. 3B, lanes 3 and 4) demonstrated that a single fragment
of approximately 1.27 kb was amplified from the diseased
kidneys. This fragment was the same size as that amplified
from control REB-c plasmid DNA and contained the ex-
pected internal HindIII site (Fig. 3B, lanes 5 to 6 and 12 to
14). No bands were observed in the amplification reactions
of DNA isolated from normal uninfected kidneys (Fig. 3B,
lanes 1 and 2). This analysis demonstrates that the erbB
DNA in the diseased kidneys did not contain detectable
deletions in 3' coding sequences. This analysis does not rule
out the presence of activating point mutations. However, it
is unlikely that erbB sequences in 100% of the test chickens
would have acquired point mutations that activated the
potential of erbB to cause renal adenocarcinoma.
Very little has been reported about the disease status of
kidneys from erbB-infected birds in previous experiments.
Two erbB viruses, AEV-ES4 and td359, have been shown to
induce renal adenocarcinoma (3, 18). Both of these erbB
viruses contain mutations (4, 6) that have been demonstrated
to cause broadening of erbB disease potential (30). Retro-
spective analysis of histologic sections from our prior onco-
genicity tests revealed the induction of a low incidence of
renal neoplasia (adenoma) by a spectrum of erbB viruses.
These included viruses both with activating mutations
(AEV-H, avian angiosarcoma virus 5005, and avian angio-
sarcoma virus 4890 [11, 25, 37]) and without activating
mutations (AEV-5005 [11, 25]). This suggests that most erbB
genes have the potential to cause renal neoplasia. REB-c-
infected chickens exhibited a higher incidence and more
advanced stages of neoplasia (adenocarcinoma) than those in
previous oncogenicity tests. This increased disease potential
may be a result of the more efficient spread of the erbB
oncogene in a replication-competent vector. In our previous
tests, erbB was expressed by defective retroviruses that
required the presence of a coinfecting helper virus for
transmission.
The kidney is a major site of EGF synthesis in the body,
and EGF receptors have been demonstrated in various cells
of renal origin (2; for reviews, see references 8 and 12).
Although the roles of EGF and the EGF receptor in the
kidney are unclear, it is likely that these molecules have an
important function in renal physiology (for reviews, see
references 8 and 12). Perturbation of the EGF receptor or its
ligands may have a role in neoplastic transformation in the
kidney. There are numerous reports in which human renal
cell carcinomas demonstrate abnormally high levels of ex-
pression of the EGF receptor (9, 17, 22, 26, 35, 38). In
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FIG. 3. PCR and Southern blot analysis of REB-c-induced renal
adenocarcinoma. (A) Diagram of REB-c and its 3' structure. B,
BamHI; Bc, BclI; H, HindIII; C, ClaI; LTR, long terminal repeat.
Oligonucleotides used for PCR analysis are designated 1-5' AGT
GATGTCTGGAGTTATGGTGTGACA 3' and 2-5' CTCCTITGT
AAGGCATGTTGCTAAC 3'. (B) Southern blot analysis of dis-
eased and uninfected control kidneys. Genomic DNAs were pre-
pared from kidney tissue, digested with StuI, and amplified by PCR.
The PCR products were digested with HindIII, and both digested
and undigested products were analyzed by Southern blotting as
described in the text. Filters were hybridized to a 32P-labelled
random-primed probe generated from a PCR-amplified fragment of
REB-c (BamHI to HindIII). Lanes: 1, 2, 8, and 9, 1 ,ug of DNA from
kidneys of two different uninfected chicks; 3, 4, 10, and 11, 1 p1g of
DNA from the kidneys of two different REB-c-infected chicks; 5,
12, and 13, 100 pg of pREB-c amplified in the presence of 1 ,ug of
DNA from uninfected kidneys; 6 and 14, 100 pg of pREB-c DNA; 7,
PCR mixture containing no template. 4iX174-HaeIII molecular
weight markers are as indicated.
addition, other epithelial malignancies have been shown to
express high levels of the EGF receptor (7, 19). The dem-
onstration that a virally expressed, truncated form of the
chicken EGF receptor (erbB) can cause renal adenocarci-
noma (Fig. 1 and 2) is consistent with the hypothesis that
perturbation of the EGF receptor may have a role in neo-
plastic transformation of the kidney.
In summary, we have demonstrated a new disease poten-
tial for the nonmutated erbB oncogene. Specifically, we have
shown that a virally expressed C-terminal complete erbB
induces a 100% incidence of renal neoplasia.
We thank Steven Theroux for the Ala-477/478 and Glu-477/478
point mutants, David Brown for assistance with oncogenicity tests,
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